Quanterix CEO Kevin Hrusovsky Leads Webinar on How Biomarkers are Empowering Drug Development
Published: Sep 11, 2018
Top researchers join precision health visionary for an in-depth discussion examining how biomarkers are innovating the drug development process and shortening approval times
LEXINGTON, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced Chief Executive Officer, President and Chairman, Kevin Hrusovsky, will lead a complimentary webinar on Wednesday, Sept. 19 at 11 a.m., EDT on the power of biomarkers to disrupt drug development.
The webinar, Disrupting Drug Development with Digital Biomarkers and the Power of Precision Health, will provide an overview of the Federal Drug Administration’s (FDA) new Biomarker Qualification Program and discuss how this initiative, in conjunction with new guidance on Adaptive Trial Designs and new biomarker technologies, are accelerating clinical trials and developing safer, more effective drugs. Hrusovsky, who is also the Founder of Powering Precision Health, will share his vision for deploying new digital biomarker measurements to innovate the drug development process, drawing from his long career commercializing life science research tools.
“Biomarkers enable us to see diseases earlier in the cascade when they are at a more treatable stage, as well as measure drug response in patients for the purpose of clinical trials,” said Hrusovsky. “When coupled with technology like Quanterix’ ultra-sensitive Simoa platform, these markers can be used to complement traditional clinical endpoints, providing a much faster way to measure drug efficacy and toxicity on individual patients, ushering in new treatment options and improving human health.”
Hrusovsky will be joined by world-renowned researchers who will share how they have deployed biomarker technology in the areas of neurology and oncology research, including:
- Dr. Henrik Zetterberg, Professor of Neurochemistry and Head of the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg
- Dr. Andrew Nixon, Associate Professor in Medicine, Member of the Duke Cancer Institute
Designed for a wide range of stakeholders in healthcare, the webinar will provide a roadmap for how researchers, executives, patients, and investors alike can change the way healthcare is practiced today. Attendees will more clearly understand the impact of environmental factors on human health, how the FDA’s Biomarker Qualification Program can impact drug timelines, the implications of Adaptive Trial Design for accelerating drug development, the role biomarker detection technologies play in clinical trial endpoint considerations, and how these technologies are being used to advance the understanding of drug efficacy, toxicity, dosage response, and other parameters.
To learn more about the webinar and register, click here.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Lindsay Poole, 617-502-4300
Source: Quanterix Corporation